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Abstract: While the biopsychosocial nature of inflammatory bowel disease (IBD) is now well accepted
by clinicians, the need for integrated multidisciplinary care is not always clear to institutional
administrators who serve as decision makers regarding resources provided to clinical programs. In
this commentary, we draw on our own experience in building successful integrated care models
within a division of pediatric gastroenterology (GI) to highlight key considerations in garnering initial
approval, as well as methods to maintain institutional support over time. Specifically, we discuss the
importance of making a strong case for the inclusion of a psychologist in pediatric IBD care, justifying
an integrated model for delivering care, and addressing finances at the program level. Further, we
review the benefit of collecting and reporting program data to support the existing literature and/or
theoretical projections, demonstrate outcomes, and build alternative value streams recognized by
the institution (e.g., academic, reputation) alongside the value to patients. Ultimately, success in
garnering and maintaining institutional support necessitates moving from the theoretical to the
practical, while continually framing discussion for a nonclinical/administrative audience. While the
process can be time-consuming, ultimately it is worth the effort, enhancing the care experience for
both patients and clinicians.
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There is an ever-increasing body of evidence supporting the biopsychosocial nature of
inflammatory bowel disease (IBD). The biopsychosocial model recognizes that symptoms
and disease activity result from multiple interacting pathways including biologic (e.g.,
physiologic, genetic), psychologic (e.g., emotional, behavioral) and social (relationships,
environment) factors. It may appear obvious to clinicians that all of these areas represent
therapeutic targets which need to be addressed to provide patients with optimal physical
health and quality of life, and further that this dynamic model indicates a clear role for
both the gastroenterology (GI) physician and the psychologist in partnership in routine IBD
care. However, this need is not always so apparent to nonclinicians (e.g., administrators)
who are often the decision makers regarding the resources provided to clinical programs.
In our experience, administrators have two primary questions when considering support
for the development of multidisciplinary and interdisciplinary clinics: (1) What are the
patients’ needs and best practices for providing those needs? and, (2) What are the financial
implications of the proposed practice model? With regard to obtaining support for the
development of an IBD interdisciplinary program, the first question is more straight
forward, more empirically supported, and more consistent from health system to health
system. The second question addresses an area that continues to evolve and is somewhat
dependent, at least initially, on the billing and contracting proficiencies of a particular
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health system. In this commentary, we will address both questions and describe methods
we have found helpful for maintaining support after garnering initial approval. While
the focus of this commentary will be on pediatric IBD, and the GI physician–psychologist
partnership in IBD programs, the lessons learned can and should be applied to other
pediatric subspecialty populations and clinical providers relevant to their care. A few
examples of this broader application will be provided from our own lived experience.
2. Making the Case for Inclusion of a Psychologist in IBD Care
The first step in garnering support for embedding a psychologist in an IBD program,
and creating a multidisciplinary clinic, is to use the existing literature to develop a compelling story for inclusion of a psychologist in routine IBD care. The following is not meant
to be a comprehensive review of the literature but rather one example of how to use the
current available literature to effectively highlight the importance of mental health in IBD
to an administrative leader. The main points to cover include the fact that psychological
dysfunction is common in IBD, impacts the clinical course affecting symptoms, quality of
life, and resource utilization, and is amenable to treatment which, in turn, has a positive
impact on the disease course and costs.
Sample rationale: Pediatric patients with IBD are at increased risk for depression,
anxiety, social isolation, and altered self-image [1,2]. In fact, nearly 25% of adolescents
with IBD have symptoms of depression, and most go unrecognized without intentional
screening and evaluation [3]. Internalizing symptoms, in turn, are associated with increased pain frequency and severity and greater pain impact in pediatric IBD [4,5], as well
as lower health-related quality of life [6]. In adolescents with IBD, depression correlates
with pain, diarrhea, and weight loss [7]. More broadly, stress is associated with symptom
exacerbation and relapse, particularly in patients with anxiety and depression [8]. Given
all of this, it is perhaps unsurprising that a mental health diagnosis significantly increases
emergency department visits and inpatient stays in youth with IBD [9]. A recent systematic review further demonstrated that anxiety and depression were negatively correlated
with transition self-efficacy, likely delaying and/or disrupting the successful transfer to
adult care [10]. The negative impact that psychologic dysfunction can have on treatment
adherence appears key in understanding the relationship between internalizing symptoms
and IBD control. Adherence is negatively affected by several barriers, including (but not
limited to) the complexity of the medical regimen in pediatric IBD [11,12]. Emotional
and behavioral functioning contribute significantly to nonadherence [13] and appear to
moderate the relationship between adherence barriers and adherence, with the lowest
adherence seen in patients with higher barriers in association with higher anxiety and/or
depression [14,15]. Nonadherence rates of 2 to 93% have been reported in youth with IBD,
depending on measurement method, and is associated with poor coping strategies, anxiety,
depression, and difficulties with family and social interactions [16]. In turn, nonadherence
is associated with increased disease severity, lower rates of clinical remission, increased risk
of relapse, and increased healthcare costs [13,17,18]. In sum, anxiety and/or depression are
now known to be common in pediatric IBD, and to negatively affect IBD symptoms and
disease course, adherence, quality of life, and transition efficacy/readiness.
Fortunately, strategies exist for identifying and effectively treating at risk patients
with IBD. Appropriate screening and treatment of anxiety and depression in youth with
IBD can positively impact the clinical course and improve health-related quality of life [7].
Psychotherapy in children and adolescents with IBD and depression improves depression and general adjustment, lessens impairment, and reduces healthcare utilization including hospital admissions, emergency department visits, radiologic exams, and endoscopies [19,20]. Likewise, individually tailored psychological treatment of nonadherence,
including training in problem solving skills and—in some cases—behavior management,
self-management, and education, can significantly improve adherence rates [21–24]. Given
this mounting evidence, both the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and a task force of the ImproveCareNow
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Other information is also likely to be available in the electronic medical record (EMR)
that can be abstracted and combined with this screening data to help you make your case.
For pediatric IBD, the effects of anxiety, depression, and adherence could be assessed for
their relationship to EMR-based outcome measures including, for example, steroid-free
admission rate, emergency department visits, and hospital admission and length of stay
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near unanimous consensus that care should be provided by a multidisciplinary team which
meets regularly to discuss appropriate patients [34]. Another recent systematic review also
concluded that an integrated care model incorporating a healthcare team that included
a psychologist was the optimum model and is shown to decrease hospital admissions,
IBD surgeries, comorbidities, and both direct and indirect costs [35]. It is clear that a care
model that falls along the care spectrum between integrated multidisciplinary (in which
providers work side-by-side with real-time meaningful communication/collaboration) and
interdisciplinary (in which providers routinely see patients together) is supported by both
providers and patients.
In addition to sharing empiric evidence in favor of integrated multidisciplinary/interdisciplinary care models (hereafter referred to as integrated care), we have found it helpful
to describe personal observations to support why an integrated approach is preferred by
providers and patients alike. Providers involved in the care of IBD patients recognize the
interaction of various factors that determine patient outcomes across the biopsychosocial
model and the value of discussion in real-time with shared input to create the optimum
care plan. For example, nonadherence is a significant factor in outcome as medications
cannot be effective if they are not consumed. It is therefore important to assess adherence
and adherence barriers in the clinic, as well as psychosocial factors which may be driving
nonadherence. This allows nonadherence to be addressed in clinic and decisions to be
made regarding treatment. Is the barrier that the medication must be taken at a frequency
that does not work with the patient’s schedule and commitments? If so, thoughtful
consideration can be given to changing the medication or dosing regimen with the GI
physician present. Is anxiety or depression the primary barrier? If so, a treatment plan to
address internalizing issues can be laid out quickly with a psychologist present. From a
patient perspective, identifying a psychosocial issue or nonadherence which prompts a
referral to a psychologist at a future date, who in turn communicates back with the medical
provider who subsequently makes medication decisions, is an unsatisfactory experience
and a needless delay in care [37,38]. The patient experience is enhanced by being able to
see the relevant providers in a single visit and know that their care team is aligned in any
treatment recommendations.
4. Addressing Program Finances
Addressing the financial impact of a program can be the most challenging component
of selling your integrated care vision. Approximately half of IBD healthcare providers
perceive funding to be the greatest barrier to implementing the ideal care model [35]. The
challenges include the wide variety of evolving reimbursement models, trends towards
capitated care and shared risk models, and possible future reimbursement models centered
around delivering value to the patient, i.e., improved outcomes at decreased costs. While
pay-for-service is still the primary payment mechanism, healthcare providers need to plan
for the movement to payment systems that value high-quality care [39]. While a discussion
of the varying and evolving payment models is beyond the scope of the current paper, we
would emphasize three points in preparation for discussion of the program proposal with
administration: (1) Develop a detailed plan of the care model; (2) Develop a business plan;
and, (3) Emphasize that finances need to be assessed as total inflow minus total outflow.
First, a detailed description of the ideal clinical care model allows administration
to understand personnel and resource needs, as well as plans to maximize efficiency. In
addition, it provides the solid framework needed for development of a business plan, as
there can be more accurate assessment of start-up funds needed and on-going costs. The
business plan should also include any expansion into new markets, projected revenue,
and a marketing plan. Greater detail in both the clinical care model and business plan
tends to breed greater confidence within administrative decision-makers. It cannot be
over-emphasized that business partners need to be identified to provide data credible to
administration. However, it is equally important that the clinical team remains closely
involved in business planning to prevent data being derived from faulty assumptions
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and, instead, ensuring that they are accurate based on the experience and plans of the
clinical team. Collaboration on the business plan allows for the creation of the most
accurate, meaningful, and credible projections. Probably the most important factor in
selling and sustaining an integrated care vision is to frame the financial assessment of
the ideal clinical care model as total revenue minus total expenses for the program as
a whole, diverting the discussion away from the analysis of individual team members.
Given the different billing parameters, reimbursement rates, etc. between subspecialty
providers, the close examination of individual team members is likely to dismantle an
integrated care program. While optimizing billing for individual team members will help
the bottom line, looking at the whole (i.e., collective inflow versus outflow) more effectively
takes into account time spent by the team, especially when one team member can bill
for a portion of the clinical service (e.g., time spent in non-face-to-face interdisciplinary
collaboration) and another cannot. If the whole program meets the financial thresholds set
by the administration, it should be approved in total. If not, then parameters can be defined
and efforts made to reconcile finances without compromising the highest quality of care.
As more reimbursement becomes capitated or based on the quality of outcomes, integrated
care models are well suited to be the most cost-effective, demonstrating improved outcomes
that in turn lower costs and improve patient value.
5. On-Going Support
While existing literature supports the need for a psychologist, the superiority of
integrated care, and the financial benefits, this body of evidence only provides projections
and theoretical benefits in the eyes of administration. It is vitally important to confirm the
accuracy of these projections in actual practice once the program is implemented. This is
best accomplished by systematic data collection and utilization of a quality improvement
perspective to demonstrate need and value. Ideally, the data would be compared over
time, be used to guide care, and be published. This demonstrates professional commitment
and provides marketing opportunities to enhance program recognition and reputation,
which also serves the larger institution. Publishing data related to psychological factors
and adherence provides credibility to the initial justification and emphasizes that these are
issues in the actual population being served in a program—both critical to sustaining an
integrated care model long-term.
An important practical consideration in publishing on clinical data is the Institutional
Review Board (IRB) oversight and appropriate timing for review. The right timing needs
to be decided before any data is collected and depends on the scope of what you plan
to collect, whether you already have specific research questions in mind, and the type of
project you want to pursue. In terms of scope, if you can justify each and every measure in
your screening battery as impacting clinical care and treatment decision making for the
individual patient, and are including the results of all screening measures in your clinical
documentation, then you can consider this clinical data capture and not research. In this
case, no IRB is required up front. Instead, if/when you develop a research question that
you think you can answer with the clinical data on hand, you would submit a retrospective
chart review protocol to your local IRB for review at that time. In this scenario, your clinical
data is simply another type of EMR data that you can abstract within an IRB-approved
retrospective chart review. However, if there is even one component of your screening
battery that you cannot justify form an immediate clinical perspective, then things get
a bit more complicated. One option is to separate that measure (or measures) from the
rest of the clinical screening battery and treat that measure as research. In this case, you
would submit an IRB protocol up front to allow you to ask families to complete this “study”
measure and grant permission to allow you to also collect specific information from the
EMR (including the clinical screeners, if desired). This is a relatively clean approach in
that families would still complete all other screeners as standard clinical care and only
complete the “study” measure if they consent to participate in your IRB-approved research
study. Another option is to submit your screening battery to the IRB with a request to
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create a repository, which allows you to ask permission of families up front to use all data
collected as part of the clinical program as to answer relevant research questions as they
arise. This situation requires more up front work on approval, but it can simplify your
research process on the back end as you do not need to go back to the IRB with repeated
requests for retrospective chart review later on. Further, getting approved for a repository
opens up the possibility of including measures that you might not have included in a
purely clinical database. However, you need to ensure that you have an error-proof way of
separating those patients whose families have consented to have their data included in the
repository from those who have not, even though they are completing the same (or at least
a similar) battery as part of clinical care if they do not consent. This is critical to prevent
accidentally including families in your research who have actively opted out at an earlier
timepoint. Finally, some projects may fall into the quality improvement (QI) realm, and
be exempt from IRB review. Such projects typically focus on closing a known gap in care,
such as improving vaccination rates in IBD patients, increasing the percent of patients seen
for a clinic visit within the recommended follow up period, or even improving the rates
of behavioral health follow up in patients who screened above a depression cutoff. The
process for QI determination differs from institution to institution, but specific guidance
should be available by calling your local IRB office.
Examples of work published from the IBD program at our institution include, among
others, demonstration of the value of screening for psychological dysfunction [40], examination of patient and family perspectives on barriers to transition and transfer of care [41],
documentation of high rates of both accidental and volitional nonadherence associated
with increased disease severity and decreased quality of life [42], and development of a
measure to assess accuracy of patient and caregiver knowledge of disease and treatment
regimen [43]. Although pediatric IBD is the focus of this commentary, we have employed a
similar approach across several other chronic GI conditions with success. Perhaps most
notably, and certainly the most long-standing of which is our chronic abdominal pain
program. With this program, we have been able to improve our clinical data collection iteratively over time to refine our process, align them with emerging knowledge, generate new
knowledge, and utilize our data for individual patient monitoring and programmatic quality improvement efforts. Specifically, we have published multiple papers demonstrating
psychologic disturbances in patients with chronic abdominal pain including interactions
with functional disability, sleep, pain severity, and gastrointestinal inflammation [44–47].
We have published outcome data for a large population of children with chronic abdominal
pain treated in our interdisciplinary program [48]. Further, we have demonstrated that
anxiety and sleep disturbances are associated with poorer initial response to treatment in
youth with chronic abdominal pain [48]. In one of our newer programs, we have demonstrated that poor adherence to lab testing in a liver transplant population is associated
with significant consequences [49]. These manuscripts, like those noted in IBD above, have
provided tangible peer-reviewed data demonstrating an on-going need for psychology as
an integral part of the care program. Of note, it has been helpful to collect data on patient
and family satisfaction and outcomes. We were able to demonstrate that an integrated
care model for chronic abdominal pain that involved a GI physician and a psychologist
was associated with increased caregiver satisfaction and greater receptivity to adhere to
treatment recommendations (both medical and psychosocial) [50], thus providing indirect
support for all of our integrated care programs. Most of these examples were made possible by systematically collecting data across biologic, psychologic, and social realms with
subsequent evaluation of the interactions between these factors and with outcomes.
Patient-reported outcomes and satisfaction, along with the incidence of comorbidities,
emergency department visits, and hospitalizations, should be combined with financial
performance metrics to determine value, particularly from a patient perspective. We
would recommend reporting this data up the administrative ladder on a regular basis
(e.g., semiannually). The preemptive sharing of data, particularly when there are tangible
academic products included, tends to decrease the chances of the program being part of

Children 2021, 8, 286

8 of 10

future administrative discussions regarding budget cuts. While the most important goal
is to build an excellent program which delivers outstanding patient care and outcomes,
program maintenance and growth can be enhanced by taking every available opportunity
to demonstrate the importance and value to the financial decision makers.
6. Conclusions
For clinicians, the discussion has moved well past whether psychologists should
be considered an integral member of the IBD healthcare team to how to best implement
integrated care in practice. Our goal in this commentary was to describe methods we
have found helpful to leverage institutional support to build and maintain integrated
multidisciplinary care models in pediatric IBD and other GI populations, but these steps
and lessons learned could easily be applied to the building of integrated programs in
other pediatric subspecialties, as well. First and foremost, to attain the necessary resources
to optimize care and outcomes, the healthcare team needs to undertake an intentional
process to educate administrative leaders on the current literature, local patient needs,
and best practices. It also is imperative to directly assess program finances (i.e., collective
inflow versus outflow) and value delivery in both the initial process and on an on-going
basis. While we have offered some advice, it is essential to make an assessment that
incorporates current institutional billing capabilities, while also identifying opportunities
for improving billing practices. Finally, success in garnering and maintaining institutional
support necessitates moving from the theoretical to the practical, by collecting and using
local data to demonstrate need, outcomes, and value to the institution. While the process
can be time-consuming, ultimately it is worth the effort, enhancing the care experience for
both patients and clinicians.
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